Angiosarcoma of the breast gland: molecular genetic profile, diagnosis and treatment

Angiosarcoma is a rare, aggressive tumor arising from the endothelial cells of blood vessels that can affect internal organs, but the most common location is the skin. The article presents current data on the molecular genetic profile, diagnosis and treatment of primary and secondary angiosarcomas of the breast. A search for relevant sources was carried out in the PubMed, Cochrane Library and eLibrary systems, publications from 2012 to 2023 were examined, 29 of which were used to write this review.no standard treatment guidelines, and the optimal approach remains surgical resection to achieve negative resection margins. The role of neoadjuvant, adjuvant chemotherapy and radiotherapy remains controversial.

1. Saribekyan E.K., Bosieva A.R., Medvedev S.V. et al. Postradiative angiosarcoma of the breast: a rare clinical case. Zlokachestvennye opukholi = Malignant Tumors 2023;13(2):7. (In Russ.). DOI: 10.18027/2224-5057-2023-13-2-7

2. Smith T.L., Morris C.G., Mendenhall N.P. Angiosarcoma after breastconserving therapy: long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol 2014;53(2):235–41. DOI: 10.3109/0284186X.2013.819117

3. Ghareeb E.R., Bhargava R., Vargo J.A. et al. Primary and radiationinduced breast angiosarcoma: clinicopathologic predictors of outcomes and the impact of adjuvant radiation therapy. Am J Clin Oncol 2016;39(5):463–7. DOI: 10.1097/COC.0000000000000077

4. Fedenko A.A., Konev A.A., Anurova O.A. et al. Angiosarcomas. Sarkomy kostei, miagkikh tkanei i opukholi kozhi = Bone and Soft Tissue Sarcomas, Tumors of the Skin 2013;1:24–41. (In Russ.).

5. Mantilla J.G., Koenigsberg T., Reig B. et al. Core biopsy of vascular neoplasms of the breast: pathologic features, imaging, and clinical findings. Am J Surg Pathol 2016;40(10):1424–34. DOI: 10.1097/PAS.0000000000000668

6. Rosen P.P., Kimmel M., Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988;62(10):2145–51. DOI: 10.1002/1097-0142(19881115)62: 10<2145::aid-cncr2820621014>3.0.co;2-o

7. Wang X.Y., Jakowski J., Tawfik O.W. et al. Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 2009;13(3):147–50. DOI: 10.1016/j.anndiagpath.2009.02.001

8. Rohan V.S., Hanji A.M., Patel J.J. et al. Primary angiosarcoma of the breast in a postmenopausal patient. J Cancer Res Ther 2010;6(1):120–2. DOI: 10.4103/0973-1482.63543

9. Strobbe L.J., Peterse H.L., van Tinteren H. et al. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 1998;47(2):101–9. DOI: 10.1023/a:1005997017102

10. Brooks T., Hurley L. The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer 2009;9(12):849–61. DOI: 10.1038/nrc2733

11. West J.G., Weitzel J.N., Tao M.L et al. BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer 2008;8(6):533–7. DOI: 10.3816/CBC.2008.n.066

12. Meyer N., Penn L. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8(12):976–90. DOI: 10.1038/nrc2231

13. Fraga-Guedes C., André S., Mastropasqua M.G. et al. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression. Breast Cancer Res Treat 2015;151(1):131–40. DOI: 10.1007/s10549-015-3379-2

14. Manner J., Radlwimmer B., Hohenberger P. et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema Am J Pathol 176;1:34–9. DOI: 10.2353/ajpath.2010.090637

15. Zietz C., Rossle M., Haas C. et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998;153(5):1425–33. DOI: 10.1016/S0002-9440(10)65729-X

16. Naka N., Tomita Y., Nakanishi H. et al. Mutations of p53 tumorsuppressor gene in angiosarcoma. Int J Cancer 1997;71(6):952–5. DOI: 10.1002/(sici)1097-0215(19970611)71:6<952::aid-ijc7>3.0.co;2-x

17. Wei Y., Yang X., Gao L. et al. Differences in potential key genes and pathways between primary and radiation-associated angiosarcoma of the breast. Translati Oncol 2022;19:101385. DOI: 10.1016/j. tranon.2022.101385

18. West J.G., Weitzel J.N., Tao M.L. et al. BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer 2008;8(6):533–7. DOI: 10.3816/CBC.2008.n.066

19. Kirschner K.M., Sciesielski L.K., Scholz H. Wilms’ tumour protein Wt1 stimulates transcription of the gene encoding vascular endothelial cadherin. Pflugers Arch 2010;460(6):1051–61. DOI: 10.1007/s00424-010-0873-6

20. Wooster R., Weber B.L. Breast and ovarian cancer. N Engl J Med 2003;348(23):2339–47. DOI: 10.1056/NEJMra012284

21. Milne R.L., Osorio A., Ramón y Cajal T. et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2010;119(1):221–32. DOI: 10.1007/s10549-009-0394-1

22. Easton D.F., Bishop D.T., Ford D., Crockford G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52(4):678–701.

23. Li Q., Zhang Y., El-Naggar A.K. et al. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res 2014;12(6):901–11. DOI: 10.1158/1541-7786.MCR-14-0089

24. Lahat G., Dhuka A.R., Hallevi H. et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010;251(6):1098–106. DOI: 10.1097/SLA.0b013e3181dbb75a

25. Kadouri L., Sagi M., Goldberg Y. et al. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations. Breast Cancer Res Treat 2013;140(1):207–11. DOI: 10.1007/s10549-013-2621-z

26. Wada M., Horinaka M., Yasuda S. et al. PDK1 is a potential therapeutic target against angiosarcoma cells. J Dermatol Sci 2015;78(1):44–50. DOI: 10.1016/j.jdermsci.2015.01.015

27. Stacchiotti S. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian rare cancer network. Ann Oncol 2012;23(2):501–8. DOI: 10.1093/annonc/mdr066

28. Pervaiz N. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer.2008;113(3):573–81. DOI: 10.1002/cncr.23592

29. Woll P.J. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected softtissue sarcoma (EORTC 62931): a multicentre randomized controlled trial. Lancet Oncol 2012;13(10):1045–54. DOI: 10.1016/S1470-2045(12)70346-7

30. Suzuki Y., Taniguchi K., Hatono M. et al. Recurring radiationinduced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report. Surg Case Rep 2020;6(1):25. DOI: 10.1186/s40792-020-0790-7